Understanding the role of the AhR/AhRR/CYP1A1 axis in lung cancer progression is of importance to improve current therapeutic approaches and develop new therapeutic strategies for the treatment of NSCLC. This evidence concerns the gene AHRR and non-small cell lung carcinoma.